“soliris” Archives

in
Entry Author Date Location
Alnylam Gets $800M From Regeneron to Bring RNAi to Eye, Brain Diseases 04/08/19 Boston
With Its First Human Data, Solid Slips in Duchenne Gene Therapy Race 02/07/19 Boston
Bio Roundup: Trials to Watch, Mega Deals, Video Game Therapy & More 12/08/17 Boston
Bio Roundup: CBO’s Praise, Celgene’s Shock, Trump’s Opioid Plan & More 10/27/17 National
Families Fret As Insurers Mull Biogen’s $750K Spine Disease Drug 01/06/17 National
With Insider Help, Ra Pharma Upsizes IPO, Bags $92M 10/25/16 Boston
Taking Aim at Alexion, Ra Pharma Heads to IPO Queue 10/03/16 Boston
Sarepta Preps For Sales As Insurers Unlikely To Deny Duchenne Drug 09/22/16 Boston
Duchenne Lessons: Advocates For Rare Spinal Disease Have Eyes on FDA 08/26/16 National
East Coast Biotech Roundup: Homology, Biogen, Intellia & More 05/05/16 Boston
For San Antonio’s Consideration: A Biotech Incubator and Accelerator 04/08/16 Texas
East Coast Biotech Roundup: Biogen, RaNA, Inotek, Disruptors & More 07/24/15 Boston
Ra Pharma Gets $58.5M in Crossover Cash to Target Rare Blood Disease 07/23/15 Boston
Alexion Shells Out $8.4B for Synageva In Rare Disease Mega-Deal 05/06/15 Boston
The Innovation Challenge: Assessing BioPharma Startups 05/04/15 Seattle
ASH Roundup: Immunotherapy Stars, Gene Therapy Leaps Ahead 12/11/14 San Francisco
Prescription Drug Pricing: The Fine Line Between Value and Greed 12/02/14 Boston
With $22M, True North Points Toward Rare-Disease Clinical Trials 06/17/14 San Francisco
iPierian Nabs $30M To Keep Alzheimer’s, Autoimmune Drugs Moving 09/04/13 San Francisco
Fighting a Global War on Rare Diseases 03/20/13 New York
EnerNOC Acquires M2M, H3 Launches With Eisai Funding, Genzyme Talks With Sanofi Advance, & More Boston-Area Deals News 02/02/11 Boston
Alexion Pharma Gobbles Up Taligen in $111M Buyout 01/31/11 Boston
Page 1 of 1